Mercachem logo voor websites


Update COVID-19:

The COVID-19 situation is currently impacting most of the globe, including Asia, Europe and North America. At all MercachemSyncom sites, we follow the recommendations of the local competent authorities as they are released. We have established a series of contingency measures aimed at reducing risks for our employees, their families and the MercachemSyncom Operations. These measures are proactively being reassessed at regular intervals and adapted as deemed appropriate.

The MercachemSyncom team is united and determined to face the situation with the energy, strength and passion that constitute one of our hallmarks.


 

 

Mercachem  first milestone Almirall

In December 2016, Mercachem and Almirall announced  that Almirall had obtained exclusive rights to Mercachem’s cytokine blockers, and a research collaboration was initiated to optimize these molecules towards candidates for clinical development.

Today, Mercachem is proud to announce the achievement of the first milestone of this research collaboration.

We are delighted to announce that we have achieved the first milestone within 15 months of collaboration,” said Eelco Ebbers, co-founder and Managing Director of Mercachem. “This shows the innovative research capabilities of Mercachem to progress challenging targets and chemistries, and also demonstrates the true strength of working in partnerships.” 

 

Full Press Release